Psilocybin in Cancer Pain Study
This open-label, single-group assignment trial (n=15) aims to assess the feasibility, safety, and preliminary efficacy of psilocybin-assisted therapy for opioid-refractory pain in patients with advanced cancer.
Details
Phase 2, open-label, single-center trial evaluating a palliative-care informed psilocybin-assisted psychotherapy regimen for opioid-refractory pain in advanced cancer (n≈15).
Procedures include screening, ECG and blood tests, two preparation sessions, one in-clinic oral psilocybin session, integration sessions (day after and one week after), and follow-up visits through 12 weeks to assess safety, feasibility, and pain outcomes.
Study drug provided by Filament Health; funded by Cy Biopharma and Pancreatic Cancer North America; conducted at Dana-Farber Cancer Institute.